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Background
It is 20 years since the introduction of levosimendan 
in clinical use for short-term treatment of acutely de-
compensated heart failure — one of few novel medical 
treatments made available in recent times for the acute 
heart failure management. Levosimendan has been 
authorized for clinical use in over 60 countries and 
territories, and further activities are currently ongoing 
aimed at introducing it in China and the USA. In this 
issue of the Medical Research Journal, a review by 
Tritapepe et al. [1] systematically describes how this 
drug came to be and has been used in clinics in the 
last two decades. On our side, we wanted to highlight 
with this short editorial the most prominent features of 
levosimendan as a molecule and as a drug.
Levosimendan is an inodilator that augments car-
diac contractility primarily via calcium sensitization of 
cardiac troponin C and mediates vascular dilatation 
via the opening of adenosine triphosphate-sensitive 
potassium (KATP) channels in vascular smooth muscle 
cells; the drug also exerts ischemia-protective action 
via a similar effect on mitochondrial KATP channels in 
several organs including the heart [2]. Of further note is 
that levosimendan promotes inotropy without increasing 
myocardial oxygen consumption. These aspects may 
be relevant in critical illness, when patients may be in 
a state of precarious energy balance. 
Acutely decompensated heart failure
Levosimendan has been developed as a treatment 
for acutely decompensated heart failure. The efficacy 
and safety of levosimendan in its core indication have 
been established in randomized controlled trials involv-
ing over 9000 patients, supplemented by real-world 
experience. Comparison with other cardio- and vaso-
active drugs meant for use in acute cardiac care shows 
superiority in hemodynamic, neurohormonal, and 
symptomatic effects without a sign of compromising 
long-term survival [3]. Since the beginning, however, 
its multifaceted pharmacology identified levosimendan 
as a drug that may have applications in a range of other 
critical illness situations. The conceptual framework for 
this wider use has been outlined in various recent critical 
care focused publications [4, 5].
Perioperative hemodynamic support 
Despite a strong rationale and the comfort of many 
successful pilot studies [6] peri-operative use of levo-
simendan was not associated with a statistically signif-
icant impact on overall mortality in high-risk patients 
undergoing cardiac surgery in none of three recent trials 
[7]. However, a trajectory towards a survival benefit from 
levosimendan was noted in the LEVO-CTS trial, which 
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also produced suggestions of greater clinical benefit in 
patients with severely reduced preoperative left ventricu-
lar ejection fraction (LVEF) < 35%. In fact, pre-specified 
supplementary analyses confirmed a survival benefit in 
patients undergoing isolated coronary artery bypass 
grafting [8]. These tendencies have been corroborated 
in a meta-analysis that also identified a reduced risk 
of post-operative low cardiac output syndrome and 
reduced mechanical support requirements in patients 
with pre-operative LVEF < 35% (p = 0.05) [4]. Additional 
notable findings included a lower overall incidence of 
acute kidney injury (p = 0.02) and less need for renal 
replacement therapy (p = 0.02). These latter findings 
speak to the proposition, addressed below, that spe-
cific renal actions of levosimendan—exercised at both 
glomerular and systemic hemodynamic levels —exert 
important renal-protective effects [9].
In septic shock
A plurality of theoretical considerations, experimen-
tal research and data from small clinical trials posit 
a beneficial impact of levosimendan in septic shock [5]. 
Against these must be set the findings of the LeoPARDS 
trial [10] that suggests that the use of levosimendan 
in septic shock patients may confer no overall clinical 
benefit in term of organ dysfunction prevention. In case 
of severe septic cardiomyopathy. Further research 
is needed to examine interplay with the degree of 
severity of cardiac failure plus the influence (if any) of 
treatment timing. In addition, the risk associated to the 
excessive use of vasoactive amines led to consider 
different approaches for the management of septic 
patients; in this context, levosimendan may represent 
a useful alternative to dobutamine in patients requiring 
inotropes, especially in case of concomitant ischemic 
cardiomyopathy. 
In weaning from respiratory and 
circulatory supports 
A substantial percentage of intubated patients in 
ICUs are difficult to wean from mechanical ventilation, 
with impacts on morbidity and mortality. Next to the 
problem of congestion in ventilatory weaning failure, 
is the development of diaphragm weakness. The 
pathophysiology of the latter process is complex but 
includes altered calcium sensitivity of the contractile 
proteins. Hence it is plausible that levosimendan may 
improve the prospects for successful weaning in some 
of these patients [11], although the only completed clin-
ical study investigating this proposition has produced 
equivocal results and no indication of improved dia-
phragmatic neuromechanical efficiency but significant 
increases in both tidal volume and minute ventilation 
[12].  In the arena of weaning extracorporeal life sup-
port, there is evidence that levosimendan has some 
pertinent advantages over other inotropes, including 
no increase in myocardial oxygen consumption and 
an improvement in ventriculo-arterial coupling together 
with a prolonged cardiovascular effect and improvement 
in endothelial function [13].
Renal function
Exploratory clinical studies suggest a renal-pro-
tective effect of levosimendan in a range of cardiac 
low-output states that may be relevant to critical care or 
cardiorenal syndrome [8]. Pertinently, detailed clinical 
research has both clarified the effects of levosimendan 
on the glomerular vasculature and demonstrated that 
levosimendan-induced augmentation of glomerular 
filtration rate does not compromise renal oxygenation 
[14], thus differentiating levosimendan in functionally 
important ways from agents such as dobutamine [15] 
and milrinone [16]. 
Conclusions
Taken overall, the experience of the use of levosim-
endan in critical care settings is affirmative and the drug 
safety was proven even in such severe conditions. The 
effects of levosimendan differentiate in important ways 
from those of other cardio- and vasoactive drugs 
routinely used in the ICU. Nevertheless, it must be 
recognized that the size and power of some of the ex-
tant studies are limited and that many of the beguiling 
signals of clinical advantage that have been registered 
are in need of verification in larger, well-configured 
controlled trials. Experts’ commentary on these out-
comes nevertheless asserts the continuing potential 
of levosimendan [7]. The breadth of the exploratory 
applications in critical care scenarios may be regarded 
as a dividend of the original research program from 
which levosimendan emerged. An early commitment to 
detailed appreciation of this drug’s pharmacology and 
effects on cellular processes has provided a basis from 
which the ingenuity of clinical researchers has been able 
to identify potential new applications. Levosimendan, 
therefore, enters its third decade in clinical service with 
much still to offer in a range of situations beyond acute 
heart failure. 
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